Comments on: Biogen Wins Tysabri Case – Plans To Grow By Expanding MS Pipeline http://blog.bioasis.ca/?p=1857 The Science of Melanotransferrin (p97) Thu, 02 Sep 2010 15:27:11 +0000 hourly 1 http://wordpress.org/?v=3.0 By: Pfizer and Eisai Avoid Aricept Deal-Breaker | Bioasis Technologies Inc. http://blog.bioasis.ca/?p=1857&cpage=1#comment-227 Pfizer and Eisai Avoid Aricept Deal-Breaker | Bioasis Technologies Inc. Wed, 07 Oct 2009 16:02:33 +0000 http://blog.bioasis.ca/?p=1857#comment-227 [...] have already seen one example of this a few weeks back, when Elan soured its relationship with Biogen and almost lost its rights to Tysabri when it struck a deal with Johnson and Johnson (JnJ). JnJ [...] [...] have already seen one example of this a few weeks back, when Elan soured its relationship with Biogen and almost lost its rights to Tysabri when it struck a deal with Johnson and Johnson (JnJ). JnJ [...]

]]>